We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy for CAD Shows Promise

By Biotechdaily staff writers
Posted on 23 May 2002
A study of a new therapeutic procedure utilizing a gene product designed to produce a protein that promotes blood vessel growth in the heart shows promise for treating patients with coronary artery disease (CAD). More...
The multicenter study, reported in the March 2002 issue of Circulation, was the first trial of intracoronary gene therapy.

Currently available treatment options for coronary artery disease include drug therapy, angioplasty and bypass surgery. A nonsurgical treatment, therapeutic angiogenesis is performed via catheterization – the insertion of a tiny tube into the blood vessels surrounding the heart in order to deliver a growth factor gene into the coronary arteries. For this experimental therapy, a product called growth factor gene is then delivered through the tube into the coronary arteries.

In the first phase of the current study, 79 patients between the ages of 30 and 75 and diagnosed with mild to moderately severe stable angina. All underwent catheterization, with 60 of the patients receiving a growth factor gene, and the remaining 19 received a placebo. None of the patients or investigators in the double-blind study knew who received the active therapy until the end of the study.

To evaluate the effectiveness of the treatment, patients underwent exercise treadmill testing at 4 weeks and 12 weeks following treatment. Patients who had received the growth factor gene, or therapeutic angiogenesis, showed a larger improvement in exercise ability than those patients in the placebo group. The therapy appeared to be safe and well tolerated with no major adverse effects.

"This research has taken an initial, but significant, step in a new direction in the treatment of coronary artery disease,” said Dr. Matthew Watkins, associate professor of medicine at the University of Vermont (Burlington, USA) and one of the lead authors. It leads towards a treatment, which does not involve a mechanical solution or standard drug therapy, that may be of particular benefit to patients with chronic angina who are not good candidates for additional angioplasty or bypass surgery. We are encouraged by these results and look forward to the findings from the Phase 3 trial.”




Related Links:
The University of Vermont

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.